What You Should Know:
- 40 percent of
the global disease burden could be addressed with known interventions, but that
leaves 60 percent unaddressed.
- As part of the recent McKinsey report Prioritizing
health: A prescription for prosperity, the McKinsey Global Institute identified
ten promising innovations that can reduce total disease burden 6-10% by 2040.
- By identifying and estimating the potential scope of
innovations in the pipeline, we find that these technologies could
Read More
Digital Therapeutics | Digital Health | Evidence-Based Therapeutics Interventions
Scripps Research, Repurpose.AI Partner to Develop COVID-19 Therapeutics
What You Should Know:
- Repurpose.AI, has partnered with Scripps Research to
discover drug candidates that may be repurposed to treat COVID-19.
- The partnership will leverage Repurpose.AI's ActivPred
AI Drug Discovery Platform, an unbiased drug, target, and disease agnostic
digital chemistry engine, to discover drug candidates to treat COVID-19.
Scripps Research is
teaming up with Repurpose.AI, an AI
drug discovery company to develop COVID-19 therapeutics. The
Read More
Kaia Health Lands $26M to Expand AI-Driven Digital Therapeutics for MSK Conditions & COPD
What You Should Know:
- Digital therapeutics company Kaia Health raises $26M in
Series B funding to help grow its digital therapy solutions for musculoskeletal
(MSK) conditions, and expand into new conditions.
- The investment was led by Optum Ventures, Idinvest and
capital300, plus participation from Balderton Capital, Heartcore Capital and
Symphony Ventures, an investment partnership with world #1 golfer Rory McIlroy.
- Kaia Health’s smartphone-based
approach to managing chronic
Read More
5 Reasons Why Providers Need Electronic Support for Glycemic Management
It’s no secret hyperglycemia and hypoglycemia are associated with adverse outcomes in hospitalized patients. We’ve known for many years that hyperglycemia is widespread in the hospital, causes immune dysfunction, higher rates of infection, a longer length of hospital stay, complications, and even death.
Insulin has been the most effective therapy for hyperglycemia since it was first created almost 100 years ago, but it can also be dangerous if not managed properly. In fact, nearly 50% of all
Read More
Sharecare Acquires Evidence-Based Behavior Change Apps MindSciences
What You Should Know:
- Sharecare announced the acquisition of Boston-based MindSciences, an evidence-based behavior change suite of apps focused on mental health (anxiety, stress management), smoking cessation, and weight loss/binge eating, and more.
- The acquisition rounds out Sharecare’s portfolio of mHealth-based therapeutic programs improving chronic disease risk and overall health outcomes by targeting varying aspects of well-being.
- Based on the work of Dr. Judson Brewer, now
Read More
The DNA Company Acquires AI Digital Therapeutics App for $30M to Form My Next Health
What You Should Know:
- DNA Company acquires AI-based digital therapeutics app My Pain Sensei (MPS) to form My Next Health and is building a COVID-19 risk assessment platform to help people understand their risks of developing serious COVID-19 complications.
- The acquisition combines functional genomics with conversational AI for patient self-management apps and disease tracking tools designed to inform clinician-patient interactions.
Leading functional genomics provider The
Read More
Biofourmis Acquires Digital Therapeutics Oncology Startup Gaido Health
What You Should Know:
- Boston-based digital therapeutics startup Biofourmis acquires LA-based Gaido Health from Takeda Pharmaceuticals, in a strategic deal that expands Biofourmis’ portfolio in the oncology space.
- Gaido Health—a digital therapeutics company focused on the oncology market—was part of Takeda Digital Ventures, Takeda’s corporate technology investment and incubation arm.
- With Gaido Health’s and Biofourmis’ dual focus on remote monitoring with wearables
Read More
What Health IT Thought Leaders Say HIMSS20 Would Have Focused On—If It Had Happened
What You Need to Know:
Health IT thought leaders share what HIMSS20 would have focused On—if It had happened.
- Hot topics include health IT to address COVID-19; artificial intelligence; EHR interoperability and usability; and more.
–Kuldeep Singh Rajput, CEO of Biofourmis, Boston, Mass., which provides digital therapeutics that power personalized predictive care
“Remote monitoring platforms and clinical-grade wearables combined with artificial intelligence [AI]-based
Read More
Hong Kong’s Dept. of Health Taps Biofourmis’ Remote Monitoring Platform to Fight Coronavirus
What You Need to Know:
- Boston-based Biofourmis’ AI-powered digital therapeutics technology has inked a deal with The University of Hong Kong and Hong Kong’s Department of Health to leverage its wearable, AI-powered remote monitoring platform to provide new insights to fight COVID-19 in a national disease monitoring program.
- Biofourmis’ technology will remotely monitor coronavirus infected and suspected patients and apply personally predictive analytics to help patients and increase
Read More
Welldoc, Redox Partner for Bidrectional EHR Integration with BlueStar App
- Welldoc and Redox announce a partnership to ensure bidirectional integration with EHR with Welldoc's digital health solution for diabetes management, BlueStar.
- This partnership will allow providers to receive and review insights about users of Welldoc's BlueStar digital health app for diabetes management directly within their EHR at the point of care.
Welldoc, a digital health
company revolutionizing chronic disease management, announced today its
strategic partnership
Read More
